A. R. Greenblati, D. J. Ameer-b, and . Shader-r, Probenecid impairment of acetaminophen and lorazepam clearance. Direct inhibition of ether glucuronide formation

, J. Pharmacol. Exp. Ther, vol.234, pp.345-349, 1985.

B. H. Acyclovir, , pp.322-334

B. D. , ;. N. Biron-k, and . Furman-p.a, Viral resistance, clinical experience. Scand, J.Infect.Dis, vol.47, pp.155-164, 1985.

B. ;. Krenitsky-t, Acyclovir prodrugs: the road to valaciclovir, Drugs Fut, 1993.

B. K. Ellon and G. B. , In vitro susceptibility of varicella zoster virus to acyclovir

, Antimicrob. Agents Chemother, vol.18, pp.443-447, 1980.

. R. Blum-m, . H. Liao-s, and . De-miranda-p, Overview of acyclovir pharmacokinetic disposition in adults and children, Am.J.Med, vol.73, pp.186-192, 1982.

B. G. Norlander-b and W. Alan, A Pharmacokinetics of cimetidine after single doses and during continuous treatment, Clin.Pharmacokinet, vol.6, pp.306-315, 1981.

B. R. , Cephalosporin-probenecid drug interactions, Clin. Pharmacokinet, vol.24, issue.4, pp.289-300, 1993.

B. E. Blair-a and K. K. Cutler-r, Inhibition of renal creatinine secretion by cimetidine in humans, Renal Physiol, vol.5, pp.27-30, 1982.

B. T. De-miranda-p, Metabolic disposition of BW256U87, the L-valyl ester of acyclovir, in the rat, Antiviral Res, vol.17, 1992.

B. T. De-miranda-p, Purification and characterization of an enzyme from rat liver that hydrolyses 256U87, the L-valylester prodrug of acyclovir (ZOVIRAX®), Antiviral Res, vol.20, 1993.

C. N. Balfour and H. H. , In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir, Diag Microbiol Infect Dis, vol.6, pp.255-261, 1987.

C. P. Oliver-n, Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir, JAntimicrob, vol.18, pp.103-112, 1986.

C. R. Israiliz and D. G. , Clinical pharmacokinetics ofprobenecid, Clin. Pharmacokinet, vol.6, pp.135-151, 1981.

D. G. Larder and B. A. , The clinical significance of antiviral drug resistance, Res. Viral, vol.143, pp.115-148, 1992.

D. E. Miranda, P. , S. S. Laskin-o, H. C. Krasny, and C. J. Lietman-p.s, Disposition of intravenous radioactive acyclovir, Clin. Pharmacol. Th er, vol.3, issue.0, pp.662-672, 1981.

D. E. Miranda, P. Good, and S. , Biotransformation of acyclovir to 9-carboxymethoxymethylguanine, Fed. Proc, vol.41, p.1733, 1982.

M. P. De and . Blum-r, Pharmacokinetics of acyclovir after intravenous and oral administration, J.Antimicrob.Chemother, vol.12, pp.29-37, 1983.

D. E. Miranda, P. Good, S. S. Yarchoan-r, . V. Thomas-r, . R. Blum-m et al.,

B. S. , Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex, Clin. Pharmacol. Ther, vol.46, pp.494-500, 1989.

D. E. Miranda, P. Good, and S. S. , Species differences in the metabolism and disposition of antiviral nucleoside analogs: 1-Acyclovir, Antiviral Chem.Chemother, vol.3, issue.1, pp.1-8, 1992.

D. D. Crumpacker and C. S. , Drugs five years later : Acyclovir. Ann.!nt.Med, vol.107, pp.859-874, 1987.

D. J. Stote-r, L. G. Familiar-r, and . Alexander-f, Effect of cimetidine on renal function in normal man, Clin.Pharmacol.Ther, vol.24, issue.1, pp.76-83, 1978.

. L. Eaton-d and C. D. Klaassen, Carrier mediated transport of the organic cation procainamide ethobromide by isolated rat liver parenchymal cells, J. Pharmacol. Exp. Ther, vol.206, pp.595-606, 1978.

G. B. Ellon, . A. Furman-p, J. A. Fyfe, M. P. De, . Beauchamp-l et al.,

, Selectivity of action of an antiherpetic agent, Proc. Nat!, vol.9

. Acad, . Sei, and . Usa, , vol.74, pp.5716-5720, 1977.

G. B. Ellon, The biochemistry and mechanism of action of acyclovir, J.Antimicrob.Chemother, vol.12, pp.9-17, 1983.

E. J. Zimmerman-m, E. M. Swierkosz, J. L. Goodman, and D. R. Scholl,

H. H. , Herpes simplex virus resistant to acyclovir : a study in a tertiary care center

, Ann.Intern.Med, vol.112, pp.416-422, 1990.

F. A. St, C. M. Fyfe, J. A. Rideolit, J. L. Keller-p, and G. B. Ellon, Inhibition ofHerpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9, J. Viral, vol.32, issue.2, pp.72-77, 1979.

. A. Furman-p, M. P. De, C. M. St, and G. B. Ellon, Metabolism of acyclovir in virus infected and uninfected cells, Antimicrab. Agent Chemather, vol.20, issue.4, pp.518-524, 1981.

F. A. St and C. M. Spector-t, Acyclovir triphosphate is a suicide inactivator of the Herpes simplex virus DNA polymerase, J.Bial.Chem, vol.259, issue.15, pp.9575-9579, 1984.

H. Ya and M. H. Sa-wchuk-r, Effect of probenecid on the renal and non-renal clearance of zidovudine and its distribution in cerebrospinal fluid in the rabbit, J.Phann.Sci, vol.78, pp.716-722, 1989.

H. J. Ingrand, D. Aglit, and H. Fillet-am, La résistance clinique aux antiviraux. La lettre de l, Infectialague, vol.7, issue.8, pp.261-268, 1992.

J. M. , Valaciclovir (BW256U87): The L-valyl ester of acyclovir, J.Med. Viral, 1993.

K. S. Levi-a, Impairment ofhepatic uptake ofrifamycin antibiotics by probenecid, and its therapeutic implications, Lance!, vol.2, pp.1401-1405, 1973.

K. D. Hendrix, C. W. Nerhood, L. J. Petiy-b, . S. Wood-a, J. G. Bartleti et al., Probenecid and zidovudine metabolism, Lancet, vol.26, pp.473-475, 1989.

L. J. Harrington-j, . M. Vendel-l, and . Abi-saleh-k,

L. W. Harlk and S. I. , Regional blood-brain lactate influx, Brain Res, vol.614, issue.1-2, pp.164-170, 1993.

. L. Laskin-o, J. A. Longstreth, A. Whelton, H. C. Krasny, . E. Keeney-r et al.,

L. P. , Effect of renal failure on the pharmacokinetics of acyclovir, Am.J.Med, 1982.

. L. Laskin-Ü, M. P. De, . H. King-d, . A. Page-d, J. A. Longstreth et al.,

P. S. , Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans

, Antimicrob.Agents Chemother, vol.21, pp.804-807, 1982.

. L. Laskin-o, Clinical pharmacokinetics of acyclovir, Clin.Pharmacokinet, vol.8, issue.3, pp.187-201, 1983.

T. ;. Louron and R. Kuhnz-w.;-dibbelt-l.;-knuppen, Weighted serum pools in comparison to the trapezoïdal rule for estimating AU Cs for ethinyl oestradiol, Eur.J. Clin.Pharmacol, vol.46, pp.77-81, 1994.

. Martindale, The Extra Pharmacopoeia 30th Edition

M. J. Reed-e, . H. Shepp-d, . A. Vicary-c, . E. Flournoy-n.;-kirk-l, . H. Kersey-j et al., Acyclovir for prevention of cytornegalovirus infection and disease after allogeneic rnarrow transplantation

, NEngl.J.Med, vol.318, pp.70-75, 1988.

. H. Miller-w and . L. Miller-r, Phosphorylation of acyclovir (acycloguanosine) rnonophosphate by GMP kinase, J.Biol.Chem, vol.255, pp.7204-7207, 1980.

. H. Miller-w and . L. Miller-r, Phosphorylation of acyclovir diphosphate by cellular enzymes

, Biochem.Pharmacol, vol.31, pp.3879-3884, 1982.

M. M. Somogyi, A. A. Rolan, and P. E. Bochner-f, Effect of cimetidine on renal and hepatic drug elimination : studies with triamterene, Clin.Pharmacol. Ther, vol.40, pp.400-407, 1986.

O. J. Campoli-richards-d, Acyclovir-An updated review of its antiviral activity, pharrnacokinetic properties and therapeutic efficacy, Drugs, vol.37, pp.233-309, 1989.

H. J. Schaeffer, . Beauchamp-l, M. P. De, G. B. Ellon, . J. Bauer-d et al.,

, hydroxyethoxymethyl)guanine activity against viruses of the herpes group, Nature, vol.272, issue.9, pp.583-585, 1978.

S. D. Dandliker, P. S. Flournoy-n, and J. D. Meyers, Sequential intravenous and twice daily oral acyclovir for extended prophylaxis of Herpes simplex virus infection in marrow transplant patients, Transplantation, vol.43, issue.5, pp.654-658, 1987.

S. C. , L. N. Bossoj, and . Z. Benetl, Effect of probenecid on the formation and elimination of acyl glucuronides : studies with zomepirac, Clin.Pharmacol. Ther, vol.38, pp.121-127, 1985.

S. A. Gugler-r, Drug interactions with cimetidine, Clin.Pharmacokinet, vol.7, pp.23-41, 1982.

S. A. Mclean and A. Heinzow-b, Cimetidine-procainamide pharmacokinetic interaction in man : evidence of competition for tubular secretion of basic drugs, Eur.J. Clin.Pharmacol, vol.25, pp.339-345, 1983.

S. A. Muirhead and M. R. , Pharmacokinetic interactions of cimetidine, 1987.

, Clin.Pharmacokinet, vol.12, pp.321-366, 1987.

S. A. Stockley, C. Keal, J. Rolan, and P. Bochner-f, Reduction of metformin renal tubular secretion by cimetidine in man, Br. J. Clin. Pharmacol, vol.23, pp.545-551, 1987.

S. R. Lorenzo-a, The effects of salicylate and probenecid on the cerebrospinal fluid transport ofpenicillin, aminosalicylic acid and iodide, J.Pharmacol.Exp.Ther, vol.188, p.55, 1974.

C. M. St, F. P. Lubbers, C. M. Ellon, and G. B. , Inhibition of cellular a and virally induced deoxyribonucleic acid polymerase by the triphosphate of acyclovir

A. Chemother, , vol.18, pp.741-745, 1980.

S. V. Talaricot, C. L. Stanat, S. C. , D. M. Coen, D. M. Biron et al., A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells, Nature, vol.358, pp.162-164, 1992.

V. An, C. J. Bochner, F. Keal, and J. Somogyi-a, Selectivity of the cimetidine-induced alterations of the renal handling of organic substrat es in humans. studies with anionic, cationic and zwitterionic drugs, J.Pharmacol.Exp.Ther, vol.236, pp.481-487, 1986.

W. J. Hintz, M. Mcguffin, R. W. Springmeyer, S. C. , and C. J. Meyers-j.d, Treatment of cytomegalovirus pneumonia with high-dose acyclovir, Acyclovir Symposium Am.J.Med, vol.73, pp.249-255, 1982.

W. S. Blum-m and . De-miranda-p,

. L. Smiley-m, Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating singleand multiple-dose administration to normal volunteers, Clin. Pharmacol. Ther, vol.54, issue.6, 1993.

B. D. Whiteman-p, The mechanism of action, pharmacokinetics and toxicity of acyclovir-a review, J.Jnjection, vol.6, pp.3-9, 1983.

C. K. Datta-a, J. E. Shaw, and P. J. , Acyclovir inhibition of Epstein-Barr virus replication, P 'Jc.Natl.AcadSci. USA, vol.77, issue.9, pp.5163-5166, 1980.

H. J. Field, Persistent Herpes simplex virus infection and mechanisms of virus drug resistance

, Eur.J.Clin.Microbiol.Inject.Dis, vol.8, issue.8, pp.671-680, 1989.

G. C. Mamelok-r and L. Z. Benet, Organic amon transport by basal-lateral membranes : effect of p-aminohippurate and furosemide on each other's transport, Pharmacology, vol.37, pp.268-76, 1988.

G. , M. E. Zhao-x, and . Melo-r, Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir, Lancet, vol.2, pp.706-708, 1983.

G. , M. E. Milpied, N. Prentice, H. G. , P. A. Coggon et al., Oral valaciclovir (V ALTREX ®) produces acyclovir exposure comparable to that following intravenous acyclovir in allogeneic BMT patients, 1994.

. M. Keller-p, J. A. Fyfe, . Beauchamp-l, C. M. Lubbers, . A. Furman-p et al.,

E. G. , Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities, Biochem.Pharmacol, vol.30, issue.22, pp.3071-3077, 1981.

. L. Laskin-o, . ;. Saral-r, M. P. De, and . Keeney-r.;-lietman-p.s, Pharmacokinetics and tolerance of acyclovir, a new anti-herpes virus agent

, Antimicrob. Agents Chemother, vol.21, pp.393-398, 1982.

M. ;. Svennerholm-b, One year acyclovir suppression of frequently recurrent genital herpes : a study of efficacy, safety, virus sensitivity and antibody response, Scand.Jlnfect.Dis, vol.78, pp.33-39, 1991.

N. N. Langlois-m, Occurence and characterization of acyclovir-resistant herpes simplex virus isolates : report on a two-year sensitivity screening survey, J.Med. Viral, vol.36, issue.1, pp.1-12, 1992.

. M. Richards-d, . A. Carmine-a, . N. Brogden-r, . C. ;-reel-r, and . M. Speioeit-t, Acyclovir : a review of its pharmacocynamic properties and therapeutic efficacy, Drugs, vol.26, pp.378-438, 1983.

S. D. Boehme-r.;-chernow-m, . P. Binko-b, and . R. Mattiiews-t, Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in Herpes simplex virus-infected and uninfected cells, Biochem.Pharmacol, vol.34, issue.7, pp.1049-1056, 1985.

S. R. De-clercq-e, Mécanismes d'action et de résistances aux agents antiviraux

L. , Infectiologue, vol.6, issue.15, pp.507-510, 1991.

H. H. Tilson, Monitoring the safety of antivirals. The example of the acyclovir experience

, Am.J.Med, vol.85, pp.116-122, 1988.

W. S. Dubb, J. W. , R. W. Westlake-w, and . M. Stote-r,

I. A. , Bioavailability of cimetidine in man, Gastroenterology, vol.74, pp.360-365, 1978.

W. R. Gnann and J. W. , Acyclovir: a decade later, New Engl.J.Med, vol.327, issue.11, p.782, 1992.

M. Plasmatique-pondere-(louton, ANNEXE, vol.5, 1994.

, Elle consiste à pooler le plasma des différents prélèvements d'un même sujet avec des volumes

, En effet, d'un point de vue mathématique, l'aire d'un trapèze est calculée par la formule

, /2 b x (Il + 12), où b est la base du trapèze et 11 et 12 les longeurs respectives de chacun des 0

, L'idée du pool plasmatique pondéré consiste à mélanger les prélèvements. avec des volumes proportionnels aux coefficients (poids) correspondants. La concentration de ce mélange est proportionnele à l'AUC calculée par la méthode des trapèzes. Multipliée par 4, c'est une estimation de